以葛兰素史克行贿为镜鉴,可以看到中国企业乃至中国经济的很多问题。7月,葛兰素史克(GSK)行贿一案被踢爆,指责GSK的不在少数。看病难且贵在中国本就是个热点话题,此番GSK行贿,更让人猜测,这行贿成本多半是加在药价上由消费者买单了。这边厢,中国人民声讨GSK,而那边厢,大洋彼岸的资本市场却对此并无太大反响。GSK同时在伦敦证交所和纽交所上市,行贿丑闻爆出的那两日股价不仅没跌,反倒还略微上涨了一些,实在令人费解。 GlaxoSmithKline bribed mirror, you can see many problems of Chinese enterprises and even China’s economy. In July, the case of GSK bribing was kicked off, accusing GSK of being a minority. Difficult to see a doctor and expensive in China this is a hot topic, this time GSK bribe, even more speculation that most of the cost of this bribe is added to the drug price by the consumer pay. On this side, the Chinese people denounce the GSK, while the capital markets on the other side of the oceans and the oceans have not been much affected by this. GSK was listed on the London Stock Exchange and the NYSE at the same time. The share price of the two days when the bribery scandal broke out not only did not fall, but rose slightly, which is really puzzling.